Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.
作者信息
Korkes Fernando
机构信息
Disciplina de Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil.
出版信息
Int Braz J Urol. 2021 Jul-Aug;47(4):819-820. doi: 10.1590/S1677-5538.IBJU.2020.0594.1.
Abstract
摘要
相似文献
1
Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.编辑评论：Charlson合并症评分为零的非转移性肌肉浸润性膀胱癌患者新辅助化疗使用的相关因素
Int Braz J Urol. 2021 Jul-Aug;47(4):819-820. doi: 10.1590/S1677-5538.IBJU.2020.0594.1.
2
Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.与 Charlson 共病评分为 0 且无转移的肌肉浸润性膀胱癌患者接受新辅助化疗相关的因素。
Int Braz J Urol. 2021 Jul-Aug;47(4):803-818. doi: 10.1590/S1677-5538.IBJU.2020.0594.
3
Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.新辅助化疗和辅助化疗在肌层浸润性膀胱癌中的应用趋势。
Investig Clin Urol. 2020 Nov;61(6):565-572. doi: 10.4111/icu.20200132. Epub 2020 Sep 8.
4
5
Neoadjuvant chemotherapy in patients with invasive bladder cancer.浸润性膀胱癌患者的新辅助化疗
Urol Clin North Am. 2005 May;32(2):231-7. doi: 10.1016/j.ucl.2005.03.001.
6
Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer?
Eur Urol. 2021 Mar;79(3):372-373. doi: 10.1016/j.eururo.2020.09.019. Epub 2020 Sep 24.
7
Editorial Comment on "Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer".关于“膀胱癌根治性膀胱切除患者的社会脆弱性与新辅助化疗的接受情况”的编辑评论
Urology. 2024 Sep;191:85. doi: 10.1016/j.urology.2024.06.024. Epub 2024 Jun 20.
8
Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?肌肉浸润性膀胱癌的新辅助治疗和辅助治疗：我们目前的进展如何？
Arch Esp Urol. 2020 Dec;73(10):971-985.
9
Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.肌肉浸润性膀胱癌女性患者中妇科器官受累的当代发生率：对新辅助化疗后接受根治性膀胱切除术的女性患者的回顾性研究。信函
J Urol. 2022 Feb;207(2):476-477. doi: 10.1097/JU.0000000000002306. Epub 2021 Oct 25.
10
Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply.肌层浸润性膀胱癌女性患者中妇科器官受累的当代发生率：对接受新辅助化疗后行根治性膀胱切除术的女性患者的回顾性研究。回复
J Urol. 2022 Feb;207(2):476-477. doi: 10.1097/JU.0000000000002307. Epub 2021 Oct 25.
引用本文的文献
1
Kidney function improvement after urinary diversion for cisplatin eligibility in bladder cancer patients.膀胱癌患者行尿液改道后肾功能改善以符合顺铂治疗条件。
Bladder (San Franc). 2025 Mar 3;12(1):e21200027. doi: 10.14440/bladder.2024.0034. eCollection 2025.
本文引用的文献
1
Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients.与 Charlson 共病评分为 0 且无转移的肌肉浸润性膀胱癌患者接受新辅助化疗相关的因素。
Int Braz J Urol. 2021 Jul-Aug;47(4):803-818. doi: 10.1590/S1677-5538.IBJU.2020.0594.
2
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南：2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
3
Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? | Opinion: Yes.根治性膀胱切除术是大多数肌层浸润性膀胱癌患者的最佳选择？| 观点：是。
Int Braz J Urol. 2017 Mar-Apr;43(2):184-187. doi: 10.1590/S1677-5538.IBJU.2017.02.03.
Zotero 插件